Financial Performance and Corporate Actions – H. Lundbeck A/S (2026 H1)

Revenue Growth and Commercial Momentum

  • H. Lundbeck reported total revenue growth of +16 % in constant currencies (CER) for the first half of 2026, with an underlying CER growth of +13 %.
  • The increase was primarily driven by the continued strong performance of Vyepti®, the company’s flagship medication for obsessive‑compulsive disorder and related conditions.
  • Commercial execution across the company’s portfolio was cited as a key factor in the revenue expansion.

Earnings and Profitability

  • The company’s reported earnings before interest, taxes, depreciation, and amortization (EBITDA) for H1 2026 were DKK 1,982 million, exceeding the analyst consensus of DKK 1,945 million.
  • EBITDA margin stood at 30.7 %, slightly above the consensus margin of 33.3 %.
  • Adjusted EBITDA also surpassed expectations, recorded at DKK 1,982 million versus the consensus of DKK 1,945 million.
  • Earnings per share (EPS) reached DKK 1.16 per share, compared with the consensus EPS of DKK 0.97.

Guidance and Outlook

  • H. Lundbeck’s management reaffirmed its revenue outlook for 2026, expressing confidence in the company’s pipeline and balance‑sheet strength.
  • The company highlighted progress in its research portfolio, noting the completion of recruitment for the DEEp OCEAN study involving bexicaserin.

Share‑Capital Activity

  • Lundbeckfond Invest A/S launched a voluntary exchange offer for A‑shares of H. Lundbeck.
  • The offer is part of a broader corporate governance initiative and does not affect the company’s share capital structure.

Market Context

  • Despite a short‑position pressure of 0.62 % on H. Lundbeck as of 17 August 2026, the company’s financial results and growth trajectory have been viewed positively by analysts.
  • The market cap of H. Lundbeck stands at DKK 35.7 billion, with a price‑earnings ratio of 9.9.

Summary

H. Lundbeck delivered a stronger-than‑expected first‑half performance in 2026, with robust revenue growth driven by Vyepti and solid profitability metrics. The company’s leadership remains confident in its strategic direction and pipeline development. The voluntary exchange offer by Lundbeckfond Invest reflects ongoing shareholder engagement, while short‑position data indicates continued market interest.